Masaki Nishimura1, Etsuro Yamaguchi1, Ayumu Takahashi1, Nobuhiro Asai2, Eisuke Katsuda3, Toyohiro Ohta3, Yoshinori Ohtsuka4, Kenshi Kosaka1, Ayako Matsubara1, Hiroyuki Tanaka1, Norihito Yokoe1, Akihito Kubo1, Satoshi Konno5, Kenji Baba6. 1. Division of Respiratory Medicine & Allergology, Department of Internal Medicine, Aichi Medical University School of Medicine, Aichi, Japan. 2. Department of Infection Control & Prevention, Aichi Medical University Hospital, Aichi, Japan. 3. Department of Radiology, Aichi Medical University School of Medicine, Aichi, Japan. 4. Department of Pneumoconiosis, Hokkaido Chuo Rosai Hospital, Hokkaido, Japan. 5. First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan. 6. Medical Clinic, Aichi Medical University Hospital, Aichi, Japan.
Abstract
AIM: Precise clinical significance of antigranulocyte-macrophage colony stimulating factor (GM-CSF) autoantibody levels in autoimmune pulmonary alveolar proteinosis (aPAP) has not been well studied. METHODS: We obtained sera from 50 healthy controls, 46 aPAP patients, 50 with sarcoidosis, 52 with idiopathic interstitial pneumonia and 75 with pneumoconiosis. The clinical course of aPAP patients was assessed by scoring computed tomography images in 19 patients. RESULTS: The cut-off level of anti-GM-CSF IgG for discrimination between aPAP and other diffuse lung diseases was 2.8 μg/ml with 100% sensitivity and 98% specificity. Antibody levels at baseline were significantly lower in the improved group than in the unimproved group (p = 0.008). CONCLUSION: Our results indicate the existence of threshold levels of serum anti-GM-CSF IgG for the development and persistence of aPAP.
AIM: Precise clinical significance of antigranulocyte-macrophage colony stimulating factor (GM-CSF) autoantibody levels in autoimmune pulmonary alveolar proteinosis (aPAP) has not been well studied. METHODS: We obtained sera from 50 healthy controls, 46 aPAP patients, 50 with sarcoidosis, 52 with idiopathic interstitial pneumonia and 75 with pneumoconiosis. The clinical course of aPAP patients was assessed by scoring computed tomography images in 19 patients. RESULTS: The cut-off level of anti-GM-CSF IgG for discrimination between aPAP and other diffuse lung diseases was 2.8 μg/ml with 100% sensitivity and 98% specificity. Antibody levels at baseline were significantly lower in the improved group than in the unimproved group (p = 0.008). CONCLUSION: Our results indicate the existence of threshold levels of serum anti-GM-CSF IgG for the development and persistence of aPAP.
Authors: Ali Ataya; Vijaya Knight; Brenna C Carey; Elinor Lee; Elizabeth J Tarling; Tisha Wang Journal: Front Immunol Date: 2021-11-22 Impact factor: 7.561
Authors: Renaud Prevel; Vivien Guillotin; Sébastien Imbert; Patrick Blanco; Laurence Delhaes; Pierre Duffau Journal: Front Med (Lausanne) Date: 2022-03-29